NCT04296162View on ClinicalTrials.gov

Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

178

Participants

Timeline

Start Date

March 10, 2020

Primary Completion Date

July 30, 2025

Study Completion Date

June 30, 2027

Conditions

Breast Cancer

Interventions

DRUG

Vinorelbine

Vinorelbine chemotherapy (oral)

DRUG

Capecitabine

Capecitabine chemotherapy (oral)

DRUG

Trastuzumab

Trastuzumab target therapy

Trial Locations (1)

200032

Zhi-Ming Shao, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER

NCT04296162 - Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID) | Biotech Hunter | Biotech Hunter